



This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Checkpoint kinase 1-short (Chk1-S)	In vitro and mouse studies suggest increasing levels of Chk1-S may help treat cancer. In mice bearing breast cancer tumors, overexpression of Chk1-S decreased tumor volume compared with normal Chk1-S expression. Next steps include identifying a way to increase the splicing that produces Chk1-S. Eli Lilly and Co. has checkpoint kinase 1 (Chk1) inhibitors in Phase I, Phase II and Phase I/II testing to treat cancer. Genentech Inc. has a Chk1 inhibitor to treat cancer in Phase I trials.	Unpatented; available for licensing	Pabla, N. et al. Proc. Natl. Acad. Sci. USA; published online Dec. 19, 2011; doi:10.1073/pnas.1104767109 Contact: Zheng Dong, Georgia Health Sciences University, Augusta, Ga. e-mail: zdong@georgiahealth.edu
		SciBX 5(3); doi:10.1038/scibx.2012.68 Published online Jan. 19, 2012		